The USP18 inhibitor combined with targeted therapies (sorafenib and regorafenib) significantly diminishes tumor growth in an established mouse model of multifocal HCC induced by high-pressure hydrodynamic tail vein injection of a proto-oncogene. This evidence concerns the gene USP18 and neoplasm.